<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Pharmacol Ther</journal-id><journal-id journal-id-type="iso-abbrev">Clin. Pharmacol. Ther.</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Clinical pharmacology and therapeutics</journal-title></journal-title-group><issn pub-type="ppub">0009-9236</issn><issn pub-type="epub">1532-6535</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC3837382</article-id><article-id pub-id-type="pmcid-ver">PMC3837382.1</article-id><article-id pub-id-type="pmcaid">3837382</article-id><article-id pub-id-type="pmcaiid">3837382</article-id><article-id pub-id-type="manuscript-id">NIHMS527171</article-id><article-id pub-id-type="pmid">22472995</article-id><article-id pub-id-type="doi">10.1038/clpt.2011.323</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS527171</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA527171</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Safety and Pharmacokinetics of Escalating Daily Doses of the Antituberculosis Drug Rifapentine in Healthy Volunteers</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Dooley</surname><given-names initials="KE">KE</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bliven-Sizemore</surname><given-names initials="EE">EE</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weiner</surname><given-names initials="M">M</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lu</surname><given-names initials="Y">Y</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nuermberger</surname><given-names initials="EL">EL</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hubbard</surname><given-names initials="WC">WC</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fuchs</surname><given-names initials="EJ">EJ</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Melia</surname><given-names initials="MT">MT</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Burman</surname><given-names initials="WJ">WJ</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dorman</surname><given-names initials="SE">SE</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</aff><aff id="A2"><label>2</label>Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</aff><aff id="A3"><label>3</label>Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA</aff><aff id="A4"><label>4</label>Division of Medicine and Infectious Diseases, Veterans Administration Medical Center, San Antonio, Texas, USA</aff><aff id="A5"><label>5</label>Denver Public Health, Denver, Colorado, USA</aff><author-notes><corresp id="FN1">Correspondence: KE Dooley (<email>kdooley1@jhmi.edu</email>)</corresp><fn id="FN4" fn-type="conflict"><p><bold>CONFLICT OF INTEREST</bold></p><p>The authors declared no conflict of interest.</p></fn></author-notes><pub-date pub-type="ppub"><month>5</month><year>2012</year></pub-date><volume>91</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">230106</issue-id><elocation-id>10.1038/clpt.2011.323</elocation-id><pub-history><event event-type="nihms-submitted"><date><day>07</day><month>11</month><year>2013</year></date></event><event event-type="pmc-release"><date><day>22</day><month>11</month><year>2013</year></date></event><event event-type="pmc-live"><date><day>22</day><month>11</month><year>2013</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-05 22:06:41.443"><day>05</day><month>06</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2012 American Society for Clinical Pharmacology and Therapeutics</copyright-statement><copyright-year>2012</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms527171.pdf"/><abstract><p id="P1">Rifapentine (RPT) is an antituberculosis drug that may shorten treatment duration when substituted for rifampin (RIF). The maximal tolerated daily dose of RPT and its potential for cytochrome 3A4 induction and autoinduction at clinically relevant doses are unknown. In this phase I, dose-escalation study among healthy volunteers, daily doses as high as a prespecified maximum of 20 mg/kg/day were well tolerated. Steady-state RPT concentrations increased with dose from 5 to 15 mg/kg, but area under the plasma concentration&#8211;time curve (AUC<sub>0&#8211;24</sub>) and maximum concentration (<italic toggle="yes">C</italic><sub>max</sub>) were similar in the 15- and 20-mg/kg cohorts. Although RPT pharmacokinetics (PK) appeared to be time-dependent, accumulation occurred with daily dosing. The mean AUC<sub>0&#8211;12</sub> of oral midazolam (MDZ), a cytochrome 3A (CYP3A) probe drug, was reduced by 93% with the coadministration of RPT and by 74% with the coadministration of RIF (<italic toggle="yes">P</italic> &lt; 0.01). Changes in the oral clearance of MDZ did not vary by RPT dose. In conclusion, RPT was tolerated at doses as high as 20 mg/kg/day, its PK were less than dose-proportional, and its CYP3A induction was robust.</p></abstract><funding-group><award-group><funding-source country="United States">National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID</funding-source><award-id>K23 AI080842 || AI</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>